CClinicalTrials.gg
CompletedNCT01529931OHR-8-FU-1YUpdated Jan 18, 2019

Long Term Efficiency of the Hair2Go Device

An interventional study of Hair2Go in Hair Removal, sponsored by Syneron Medical. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-18.

Sponsored by Syneron Medical · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The current study is a follow up study designed to gather information about the effect of the number of Hair2Go maintenance treatments on hair clearance 1 year after the last basic Hair2Go treatment. This study includes taking photos and documenting endpoints but does not include treatments.

Read the detailed description

The Hair2Go device is intended for short-term and long-term removal of unwanted hair adjunctive to shaving. The device uses a technology called Elōs, which is a combination of electrical field at radio frequencies (RF) and intense optical energy, that are simultaneously applied to the tissue and were found to have synergistic effects. Thus, lower levels of both energies are used to facilitate the treatment for individuals of all skin types and hair colors.

This study is a multicenter study. Subjects that completed the basic treatments of previous Hair2Go studies (OHR-2, OHR-3, or OHR-5-Face) will be offered the option to enroll in this study that will not include treatments. The individual data collected in the OHR-2 (and its extensions, i.e. OHR2-P and OHR2-1Y), OHR-3, and OHR-5-Face studies will be used for the analysis together with data gathered in this study. Photographs of the previously treated areas will be taken 3, 6, 9, and 12 months after the last basic treatment if they were not already taken as part of the OHR-2, one of its extensions (i.e. OHR2-P and OHR2-1Y), or OHR-5-Face.

02

Conditions studied

  • Hair Removal
03

In context

Lead sponsor

Syneron Medical is the lead sponsor of 41 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Completed the basic treatments of OHR-2, OHR-3, or OHR-5-Face studies.
  2. Healthy males and females, between 18 and 65 years of age.
  3. Willing to sign informed consent.
  4. Willing to follow the protocol schedule.
  5. Willingness to have photographs of the treated area taken that may be used for marketing and educational presentation and/or publications
  6. Willingness to avoid shaving 1 week prior to the visits.

Exclusion criteria

Exclusion Criteria:

  1. Subject is taking medication that may have effect on hair growth (i.e. hormones, minoxidil)
  2. Subject had electrolysis treatment within the last 6 months over the treatment area.
  3. Subject had any type of professional intense pulsed light (IPL), laser or RF hair removal in the treatment site (with the exception of treatments within the OHR-2, OHR-2P, OHR2-1Y, OHR-3, or OHR-5-Face protocol).
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Maintenance

    This arm receives Hair2Go treatments once a month for 6 months

    Device: Hair2Go

Interventions

  • DeviceHair2Go

    Hair2Go treatment once a month for 6 months

    Also known as: Mē my elōs

06

What researchers measure

Primary outcomes

  1. Hair clearance at final follow up

    Hair clearance will be calculated at the final follow-up treatment from the hair counts conducted by independent blinded reviewer(s) based on photographs of treatment sites.

    Time frame: 1 year after last basic treatment (termination)

07

Study locations

3 sites
  • South Dermatology Institute
    Tustin, California 92780, United States
  • Dr Jerome Garden
    Chicago, Illinois 60611, United States
  • Zel Skin & Laser Specialists
    Edina, Minnesota 55424, United States
08

References and documents

Individual participant data

Plan to share: No — Only 5 subjects enrolled into this protocol. Data was combined with OHR2-1Y protocol and reported under that study.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01529931
Lead sponsor
Syneron Medical
Responsible party
Sponsor
First posted
Feb 9, 2012
Start date
Jan 2012
Primary completion
Oct 2012
Completion
Nov 2012
Last update
Jan 18, 2019

Study contacts

Jerome M Garden, MD
principal investigator · Northwestern Memorial Hospital
Vince Afsahi, MD
principal investigator · South Coast Dermatology Institute
Brian D Zelickson, MD
principal investigator · Abbot Northwestern Hospital Center for Cosmetic Care
Lilach Gavish, PhD
Hebrew University of Jerusalem

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion